Oncology · PD-1 checkpoint inhibitor · clinical trial · Immune-mediated response
State of the asset · ONX-7
Synthetic demo data
KPIs for this asset
Configure| KPI | Now | 30 d ago | Target | Status |
|---|---|---|---|---|
| Strong responders ↑ | 35% | 35% (0) | 40% | 5 pp to go |
| Toxicity ≥ 50 ↓ | 3% | 1% (+2) | 8% | met |
| Fatigue (energy < 4) ↓ | 10% | 8% (+2) | 20% | met |
| At risk of discontinuation (≥ 60%) ↓ | 9% | 6% (+3) | 15% | met |
| Quality of life ↑ | 62 | 64 (-2) | 60 | met |
Outcomes
Patients kept by an action
61 / €4.5M
churn at risk now: €3.3M · 13 with nothing proven yet
Side effects · largest unsolved
Poor sleep (quality < 40)
33% now · 73% with no proven action
Emerging patterns
4
EC-01 · Delayed loss of response
Strategy
Decision memos
where it works best, regimen, diagnostics, combinations
State of the program
Active patients
500
Strong responders
192 / 38%
At-risk patients
47
Intervention opportunities
16
match trajectories that benefited from GI-04
Predicted discontinuations / 30 d
30
Emerging clusters
3
C
LIFE OS copilot · OFF
Learning at scale is not being applied to patients. Turn on Assist or Auto.
Predicted vs observed
Baseline model expectation against what the trajectories actually did.
| Metric | Predicted | Observed |
|---|---|---|
| Response | 58% | 69% |
| Severe GI toxicity | 6% | 3% |
| Discontinuation | 8% | 6% |
| Treatment persistence | 90% | 94% |
LIFE OS learned this week
All insightsA new treatment-response phenotype emerged
28 patients demonstrate early response followed by tolerance deterioration. LIFE OS flags the pattern around day 30; clinical recognition has typically come at day 77.
16 patients could benefit from intervention
Their trajectories currently resemble previous GI-04 responders. Among comparable trajectories, GI-04 reduced symptom burden by 20% and 73% improved.
State S14 predicts discontinuation
Patients entering treatment in state S14 are 6.4× more likely to reach high discontinuation risk than the program average (52 patients).
Unexpected strong responders
42 patients previously classified as moderate responders now show sustained response despite an early toxicity episode.